About: Ravidasvir

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Ravidasvir (PPI-668) is an investigational NS5A inhibitor (by ) in clinical trials for chronic hepatitis C genotype 4. Preliminary clinical trial results were announced in Nov 2015. In April 2017, press reports stated that a combination treatment involving ravidasvir and sofosbuvir had achieved a 97% clearup rate against hepatitis C in a clinical trial conducted in Malaysia and Thailand, and 100% in another conducted in Egypt. It has been granted conditional registration by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia.

Property	Value
dbo:abstract	Ravidasvir (PPI-668) is an investigational NS5A inhibitor (by ) in clinical trials for chronic hepatitis C genotype 4. Preliminary clinical trial results were announced in Nov 2015. In April 2017, press reports stated that a combination treatment involving ravidasvir and sofosbuvir had achieved a 97% clearup rate against hepatitis C in a clinical trial conducted in Malaysia and Thailand, and 100% in another conducted in Egypt. It has been granted conditional registration by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia. (en)
dbo:casNumber	1242087-93-9
dbo:chEMBL	3121849
dbo:fdaUniiCode	AL3G001BI8
dbo:pubchem	52918888
dbo:thumbnail	wiki-commons:Special:FilePath/Ravidasvir.svg?width=300
dbo:wikiPageID	49369473 (xsd:integer)
dbo:wikiPageLength	3814 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1038065257 (xsd:integer)
dbo:wikiPageWikiLink	dbc:NS5A_inhibitors dbc:Experimental_drugs dbr:Clinical_trial dbc:Gilead_Sciences dbr:Discovery_and_development_of_NS5A_inhibitors dbr:Hepatitis_C dbr:Sofosbuvir dbr:Pharco_Pharmaceuticals
dbp:atcPrefix	None (en)
dbp:c	42 (xsd:integer)
dbp:casNumber	1242087 (xsd:integer)
dbp:chembl	3121849 (xsd:integer)
dbp:chemspiderid	31141686 (xsd:integer)
dbp:h	50 (xsd:integer)
dbp:iupacName	-2 (xsd:integer)
dbp:n	8 (xsd:integer)
dbp:o	6 (xsd:integer)
dbp:pubchem	52918888 (xsd:integer)
dbp:smiles	CC[C@@H]NCOC (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	LCHMHYPWGWYXEL-ZYADHFCISA-N (en)
dbp:synonyms	PPI-668 (en)
dbp:unii	AL3G001BI8 (en)
dbp:width	275 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Reflist dbt:Use_dmy_dates dbt:Fdacite dbt:RNA_antivirals dbt:Antiinfective-drug-stub
dcterms:subject	dbc:NS5A_inhibitors dbc:Experimental_drugs dbc:Gilead_Sciences
gold:hypernym	dbr:NS
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Ravidasvir (PPI-668) is an investigational NS5A inhibitor (by ) in clinical trials for chronic hepatitis C genotype 4. Preliminary clinical trial results were announced in Nov 2015. In April 2017, press reports stated that a combination treatment involving ravidasvir and sofosbuvir had achieved a 97% clearup rate against hepatitis C in a clinical trial conducted in Malaysia and Thailand, and 100% in another conducted in Egypt. It has been granted conditional registration by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia. (en)
rdfs:label	Ravidasvir (en)
owl:sameAs	yago-res:Ravidasvir wikidata:Ravidasvir dbpedia-fa:Ravidasvir dbpedia-vi:Ravidasvir https://global.dbpedia.org/id/2N7ce
prov:wasDerivedFrom	wikipedia-en:Ravidasvir?oldid=1038065257&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Ravidasvir.svg
foaf:isPrimaryTopicOf	wikipedia-en:Ravidasvir
is dbo:wikiPageWikiLink of	dbr:Gamal_Esmat dbr:Drugs_for_Neglected_Diseases_Initiative dbr:NS5A_(hepacivirus)
is foaf:primaryTopic of	wikipedia-en:Ravidasvir

This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License